Stealing Hepatitis C's raft

Scientists have found a new drug candidate that can be used to stop the liver-damaging Hepatitis C virus (HCV) from multiplying.

NATURE AND THE NATURE RESEARCH JOURNALS PRESS RELEASE

This press release contains:
* Stealing Hepatitis C's raft - Nature Chemical Biology

PDFs of all the papers mentioned on this release can be found in the
relevant journal's section of http://press.nature.com. Press contacts for
the Nature journals are listed at the end of this release.

Warning: This document, and the Nature journal papers to which it refers,
may contain information that is price sensitive (as legally defined, for
example, in the UK Criminal Justice Act 1993 Part V) with respect to
publicly quoted companies. Anyone dealing in securities using information
contained in this document, or in advance copies of a Nature journal's
content, may be guilty of insider trading under the US Securities Exchange
Act of 1934.

PICTURES: To obtain artwork from any of the journals, you must first obtain
permission from the copyright holder (if named) or author of the research
paper in question (if not).

NOTE: Once a paper is published, the digital object identifier (DOI) number
can be used to retrieve the abstract and full text from the journal web site
(abstracts are available to everyone, full text is available only to
subscribers). To do this, add the DOI to the following URL:
<http://dx.doi.org/> (For example, <http://dx.doi.org/10.1038/ng730>). For
more information about DOIs and Advance Online Publication, see
<http://www.nature.com/ng/aop/>.

PLEASE CITE THE SPECIFIC NATURE JOURNAL AND WEBSITE AS THE SOURCE OF THE
FOLLOWING ITEMS. IF PUBLISHING ONLINE, PLEASE CARRY A HYPERLINK TO THE
APPROPRIATE JOURNAL'S WEBSITE.

*******************NATURE CHEMICAL BIOLOGY*************************
(http://www.nature.com/nchembio)

[1] Stealing Hepatitis C's raft

DOI: 10.1038/nchembio742

Scientists have found a new drug candidate that can be used to stop the
liver-damaging Hepatitis C virus (HCV) from multiplying. The research
reported in the November issue of Nature Chemical Biology showed that the
molecule keeps the virus from hijacking the lipid-making machinery in its
host cell, making it harder for the virus to replicate.
RNA-viruses like HIV and HCV are prone to drug resistance. This may be
because the drugs target proteins that the virus itself is making. To look
for new drug targets and drugs, Hiroshi Sakamoto and colleagues searched a
large number of naturally-occurring compounds for their ability to block the
replication of the virus. They found one compound, NA255 from a plant fungus
that works by blocking the host cell's ability to make certain lipids called
sphingolipids. This decreases the availability of specialized lipid
structures called rafts that the virus uses as a platform to replicate
itself.
Besides increasing our basic knowledge of how HCV replicates itself
within host cells, NA255 brings a new strategy to the anti-HCV arsenal by
targeting the host cell's machinery.

Author contact:
Hiroshi Sakamoto (Chugai Pharmaceutical Co. Ltd., Kanagawa, Japan)
Tel: +81 467 47 6773, E-mail: [email protected]

PRESS CONTACTS...

For media inquiries relating to embargo policy for all the Nature Research
Journals:
Katharine Mansell (Nature London)
Tel: +44 20 7843 4658; E-mail: [email protected]

For media inquiries relating to editorial content/policy for the Nature
Research Journals, please contact the journals individually:
Nature Biotechnology (New York)
Kathy Aschheim
Tel: +1 212 726 9346; E-mail: [email protected]

Nature Cell Biology (London)
Bernd Pulverer
Tel: +44 20 7843 4892; E-mail: [email protected]

Nature Chemical Biology (Boston)
Beatrice Chrystall
Tel: +1 617 475 9241, E-mail: [email protected]

Nature Genetics (New York)
Orli Bahcall
Tel: +1 212 726 9311; E-mail: [email protected]

Nature Immunology (New York)
Laurie Dempsey
Tel: +1 212 726 9372; E-mail: [email protected]

Nature Materials (London)
Maria Bellantone
Tel: +44 20 7843 4556; E-mail: [email protected]

Nature Medicine (New York)
Juan Carlos Lopez
Tel: +1 212 726 9325; E-mail: [email protected]

Nature Neuroscience (New York)
Sandra Aamodt (based in California)
Tel: +1 530 795 3256; E-mail: [email protected]

Nature Structural & Molecular Biology (New York)
Ed Feng
Tel: +1 212 726 9351; E-mail: [email protected]

Nature Publishing Group (NPG) is a division of Macmillan Publishers Ltd,
dedicated to serving the academic and professional scientific community.
NPG's flagship title, Nature, is the world's most highly-cited weekly
multidisciplinary journal and was first published in 1869. Other
publications include Nature research journals, Nature Reviews, Nature
Clinical Practice, and a range of prestigious academic journals, including
society-owned publications.

NPG is a global company, with headquarters in London and offices in New
York, San Francisco, Washington DC, Boston, Tokyo, Paris, Munich and
Basingstoke. For more information, please go to www.nature.com

Published: 16 Oct 2005

Contact details:

The Macmillan Building, 4 Crinan Street
London
N1 9XW
United Kingdom

+44 20 7833 4000
Country: 
Journal:
News topics: 
Content type: 
Websites: 

http://www.nature.com/nchembio NATURE CHEMICAL BIOLOGY

Reference: 

NATURE CHEMICAL BIOLOGY

Medicine